Skip to main content
SpringerLink
Log in

Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma

  • Review
  • Published:
International journal of pancreatology Aims and scope Submit manuscript

Summary

Conclusion

Gastrointestinal hormones and their antagonists can alter the growth of pancreatic adenocarcinoma in vitro and in vivo. The potential clinical benefit of this approach deserves further study.

Background

Epithelial cell growth is normally under hormonal control. Hormones also affect the growth of many epithelial cancers, and this fact is used to modify tumor growth. Pancreatic epithelial cell growth is under the influence of gastrointestinal hormones. This article reviews experiments designed to determine the effect of gastrointestinal hormones on the growth of pancreatic adenocarcinoma.

Methods

Eighty-eight articles were identified from a Medline search using the terms pancreatic adenocarcinoma and the individual names of gastrointestinal hormones. The experimental design and results of these studies are reviewed.

Results

In general, somatostatin, vasoactive intestinal polypeptide, pancreatic polypeptide, and pancreastatin inhibit pancreatic adenocarcinoma growth. Cholecystokinin, secretin, bombesin, gastrin, EGF, TGF-α, insulin, and IGF-1 have a growth-promoting effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mammal: suggestions for a new method of treatment, with illustrative cases.Lancet 1896; 2: 104–107.

    Article  Google Scholar 

  2. Huggins, C. Endocrine-induced regression of cancer, inNobel Lectures in Physiology—Medicine 1963–1970. Elsevier, Amsterdam; 1972.

    Google Scholar 

  3. Hubay CA, Arafah B, Gordon NH, Guyton SP, Crowe JP. Hormone receptors. An update and application.Surg Clin North Am 1984; 64: 1155.

    PubMed  CAS  Google Scholar 

  4. Kauppila A. Progestin therapy of endomentrial, breast and ovarian carcinoma: a review of clinical observations.Acta Obstet Gynecol Scand 1984; 63: 441.

    Article  PubMed  CAS  Google Scholar 

  5. Morisset J, Genki P, Lord A, Solomon TE. Effects of chronic administration of somatostatin on rat exocrine pancreas.Regul Pept 1982; 4: 49.

    Article  PubMed  CAS  Google Scholar 

  6. Lopez F, Esteve JP, Buscail L, Delesque N, Saint-Laurent N, Vaysse N, Susini C. Molecular mechanisms of antiproliferative effect of somatostatin: involvement of a tyrosine phosphatase.Metabolism 1996; 45(8, Suppl. 1): 14–16.

    Article  PubMed  CAS  Google Scholar 

  7. Szepeshazi K, Schally AV, Cai RZ, Radulovic S, Milovanovic S, Szoke B. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dosesomatostatin analog RC-160 on nitrosamine-induced pancreatic cancers in hamsters.Cancer Res 1991; 51: 5980–5986.

    PubMed  CAS  Google Scholar 

  8. Meijers M, Woutersen RA, Van Garderen-Hoetmer A, Baker GH, DeJong FH, Foekens JA, Klijn JGM. Effects of sandostatin and castration on pancreatic carcinogenesis in rats and hamsters.Int J Cancer 1992; 50: 246–251.

    Article  PubMed  CAS  Google Scholar 

  9. Paz-Bouza JI, Redding TW, Schally AV. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.Proc Natl Acad Sci USA 1987; 84: 1112–1116.

    Article  PubMed  CAS  Google Scholar 

  10. Redding TW, Schally AV. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.Proc Natl Acad Sci USA 1984; 81: 248–252.

    Article  PubMed  CAS  Google Scholar 

  11. Zalatnai A, Schally AV. Treatment of N-Nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160.Cancer Res 1989; 49: 1810–1815.

    PubMed  CAS  Google Scholar 

  12. Szepeshazi K, Lapis K, Schally AV. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamster.Int J Cancer 1991; 49: 260–266.

    Article  PubMed  CAS  Google Scholar 

  13. Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV. Membrane receptors for peptides in experimental and human pancreatic cancers.Pancreas 1989; 4(5): 521–528.

    Article  PubMed  CAS  Google Scholar 

  14. Srkalovic G, Ren-Zhi C, Schally AV. Evaluation of receptors for somatostatin in various tumors using different analogs.J Clin Endocrinol Metab 1990; 70(3): 661–669.

    Article  PubMed  CAS  Google Scholar 

  15. Liebow C, Hierowski M, DuSapin K. Hormonal control of pancreatic cancer growth.Pancreas 1986; 1(1): 44–48.

    Article  PubMed  CAS  Google Scholar 

  16. Liebow C, Reilly C, Serano M, Schally AV. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.Proc Natl Acad Sci USA 1989; 86: 2003–2007.

    Article  PubMed  CAS  Google Scholar 

  17. Takeda Y, Escribano MJ. Effects of insulin and somatostatin on the growth and the colony formation of two human pancreatic cancer cell lines.J Cancer Res Clin Oncol 1991; 117: 416–420.

    Article  PubMed  CAS  Google Scholar 

  18. Weckbecker G, Liu R, Tolcsvai L. Inhibitory effect of the somatostatin analog octreotide (SMS-201-995) on the growth of human and animal tumors in rodent models.Contrib Oncol 1992; 42: 362–369.

    Google Scholar 

  19. Radulovic S, Comaru-Schally AM, Milovanovic S, Schally A. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.Pancreas 1993; 8(1): 88–97.

    Article  PubMed  CAS  Google Scholar 

  20. Radulovic S, Nagy A, Szoke B, Schally AV. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.Cancer Lett 1992; 62: 263–271.

    Article  PubMed  CAS  Google Scholar 

  21. Gillespie J, Poston GJ, Schachter M, Guillou PJ. Human pancreatic cancer cell lines do not express receptors for somatostatin.Br J Cancer 1992; 66(3): 483–487.

    PubMed  CAS  Google Scholar 

  22. Poston GJ, Townsend CM, Rajaraman S, Thompson JC, Singh P. Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice.Pancreas 1990; 5(2): 151–157.

    Article  PubMed  CAS  Google Scholar 

  23. Singh P, Townsend CM, Poston GJ, Reubi JC. Specific binding of cholecystokinin, estradiol and somatostatin to human pancreatic cancer xenografts.J Steroid Biochem Mol Biol 1991; 39(5A): 759–767.

    Article  PubMed  CAS  Google Scholar 

  24. Upp JR, Olson D, Poston GJ, et al. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995.Am J Surg 1988; 155: 29–35.

    Article  PubMed  CAS  Google Scholar 

  25. Klijn JGM, Hoff AM, Th AS, Planting J, Verweij T, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.Br J Cancer 1990; 62(4): 627–630.

    PubMed  CAS  Google Scholar 

  26. Canobbio L, Boccardo F, Cannata D, Gallotti P, Epis R. Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014.Cancer 1992; 69(3): 648–650.

    Article  PubMed  CAS  Google Scholar 

  27. Huguier M, Samama G, Testart J, Mauban S, Fingerhut A, et al. Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone).Am J Surg 1992; 164: 348–353.

    Article  PubMed  CAS  Google Scholar 

  28. Fisher WE, Boros LG, Tamaddon AK, O'Dorisio MS, O'Dorisio TM, and Schirmer WJ. Somatostatin-receptor status of pancreatic adenocarcinoma predicts response to somatostatin therapy in vitro and in vivo.Surg Forum 1995; 46: 137–140.

    Google Scholar 

  29. Fisher WE, Muscarella P, O'Dorisio TM, O'Dorisio MS, Kim JA, Doran TA, Sabourin CL, Schirmer WJ. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide.Surgery 1996; 120: 234–241.

    Article  PubMed  CAS  Google Scholar 

  30. Estival A, Mounielou P, Trocheris V, Scemama JL, Slemente F, Hollande E, Ribet A. Presence of VIP receptors in a human pancreatic adenocarcinoma cell line: modulation of the cAMP response during cell proliferation.Biochem Biophys Res Commun 1983; 111: 958–963.

    Article  PubMed  CAS  Google Scholar 

  31. Ruellan C, Scemama JL, Clerc P, Fagot-Revurat P, Clemente F, Ribet A. VIP regulation of a human pancreatic cancer cell line: Capan-1.Peptides 1986; 7(1): 267–271.

    Article  PubMed  CAS  Google Scholar 

  32. Poston GJ, Yao CZ, Upp JR, Alexander RW, Townsend CM, Thompson JC. Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo.Pancreas 1988; 3(4): 439–443.

    Article  PubMed  CAS  Google Scholar 

  33. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.N Engl J Med 1994; 331: 1116–1121.

    Article  PubMed  CAS  Google Scholar 

  34. Hazelwood RL. Biosynthesis, chemistry and storage of islet (endocrine) products, inThe Endocrine Pancreas, Hadley ME, ed. Prentice Hall. Englewood Cliffs, NJ; 1989, Chap. 3.

    Google Scholar 

  35. Grossman MI, Brown JC, Said S, et al. Candidate hormones of the gut.Gastroenterology 1974; 67: 730–755.

    PubMed  CAS  Google Scholar 

  36. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides.Nature 1980; 285: 417,418.

    Article  PubMed  CAS  Google Scholar 

  37. Liu CD, Balasubramaniam A, Saxton RE, Piava M, McFadden DW. Human pancreatic cancer growth is inhibited by peptide YY and BIM-43004-1.J Surg Res 1995; 58: 707–712.

    Article  PubMed  CAS  Google Scholar 

  38. Liu CD, Slice LW, Balasubramaniam A, Walsh JH, Newton TR, Saxton RE, McFadden DW. Y2 receptors decrease human pancreatic cancer growth and intracellular cyclic adenosine monophosphate levels.Surgery 1995; 118: 229–236.

    Article  PubMed  CAS  Google Scholar 

  39. Ramo OJ, Balasubramaniam A, Sheriff S, Rogers DH, McCullough PJ, Bell RH. Neuropeptide Y and peptide YY stimulate the growth of exocrine pancreatic carcinoma.Neuropeptides 1990; 15: 101–106.

    Article  PubMed  CAS  Google Scholar 

  40. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin a novel pancreatic peptide that inhibits insulin secretion.Nature 1986; 324: 476–478.

    Article  PubMed  CAS  Google Scholar 

  41. Efendic S, Tatemoto K, Mutt V, Quan C, Chang D, Ostenson CG. Pancreastatin and islet hormone release.Proc Natl Acad Sci USA 1987; 84: 7257–7260.

    Article  PubMed  CAS  Google Scholar 

  42. Funakoshi A, Miyaska K, Nakamura R, Kitani K, Tatemoto K. Inhibitory effect of pancreastatin on pancreatic exocrine secretion in the conscious rat.Reg Peptides 1989; 25: 157–66.

    Article  CAS  Google Scholar 

  43. Smith JP, Kramer S, Bagheri S. Effects of pancreastatin (24–49) on growth of normal pancreas and pancreatic cancer.Pancreas 1991; 6(5): 551–557.

    Article  PubMed  Google Scholar 

  44. Mainz DL, Black O, Webster PD. Hormonal control of pancreatic growth.J Clin Invest 1973; 52: 2300–2304.

    Article  PubMed  CAS  Google Scholar 

  45. Pour PM, Lawson T, Helgeson S, Donnelly T, Stepan K. Effect of cholecystokinin on pancreatic carcinogenesis in the hamster model.Carcinogenesis 1988; 9(4): 597–601.

    Article  PubMed  CAS  Google Scholar 

  46. Johnson FE, LaRegina MC, Martin SA, Bashiti HM. Cholecystokinin inhibits pancreatic carcinogenesis.Cancer Detect Prevent 1983; 6: 389–402.

    PubMed  CAS  Google Scholar 

  47. Howatson AC, Carter DC. Pancreatic carcinogenesis enhancement by cholecystokinin in the hamster-nitrosamine model.Br J Cancer 1985; 51: 107–114.

    PubMed  CAS  Google Scholar 

  48. Andren-Sandberg A, Dawiskiba S, Ihse I. Studies of the effect of caerulein administration on experimental pancreatic carcinogenesis.Scand J Gastroenterol 1984; 19: 122–128.

    PubMed  CAS  Google Scholar 

  49. Corra S, Kazakoff K, Lawson RA, Adrian TE, Pour PM. Cholecystokinin inhibits DNA alkylation induced byN-nitrosobis(2-oxopropyl)amine (BOP) in hamster pancreas.Cancer Lett 1992; 62: 251–256.

    Article  PubMed  CAS  Google Scholar 

  50. Appel MJ, Meijers M, Van Garderen-Hoetmer A, Lamers CBHW, Rovati LC, et al. Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats.Br J Cancer 1992; 66: 46–50.

    PubMed  CAS  Google Scholar 

  51. Townsend CM, Franklin RB, Watson LC, Glass EJ, Thompson JC. Stimulation of pancreatic cancer growth by caerulein and secretin.Surg Forum 1981; 32: 228,229.

    CAS  Google Scholar 

  52. Shivaram S, Crist KA, Chaudhuri B, Mucci SJ, Chaudhuri PK. Effect of CCK receptor antagonist on growth of pancreatic adenocarcinoma.J Surg Res 1992; 53: 234–237.

    Article  PubMed  CAS  Google Scholar 

  53. Karsenty L, Hajri A, Aprahamian M, Garaud JC, Doffoel M, Damge C. Inhibition of growth of a transplanted rat pancreatic acinar carcinoma with CCK-8.Pancreas 1993; 8(2): 204–211.

    Article  PubMed  CAS  Google Scholar 

  54. Bell RH, Kuhlmann ET, Jensen RT, Longnecker DS. Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas.Cancer Res 1992; 52: 3295–3299.

    PubMed  CAS  Google Scholar 

  55. Smith JP, Kramer S, Solomon TE. CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium.Regul Pept 1991; 32: 341–349.

    Article  PubMed  CAS  Google Scholar 

  56. Smith JP, Rickabaugh CA, McLaughlin PJ, Zagon IS. Cholecystokinin receptors and Panc-1 human pancreatic cancer cells.Am J Physiol 1993; 265(28): G149-G155.

    PubMed  CAS  Google Scholar 

  57. Hudd C, LaRegina MC, Devine JE, Palmer DC, Herbold DR, Beinfeld MC, et al. Response to exogenous cholecystokinin of six human gastrointestinal cancers xenografted in nude mice.Am J Surg 1989; 157: 386–394.

    Article  PubMed  CAS  Google Scholar 

  58. Upp JR Jr, Singh P, Townsend CM, Thompson JC, Thompson P. Predicting response to endocrine therapy in human pancreatic cancer with cholecystokinin receptors.Gastroenterology 1987; 92: 1677 (abstract).

    Google Scholar 

  59. Alexander RW, Upp JR Jr, Singh P, Hugh T, Poston GJ, Townsend CM Jr, Thompson JC. Asperlicin inhibits the growth of a xenografted human pancreatic carcinoma.Gastroenterology 1987; 92: 1293 (abstract).

    Google Scholar 

  60. Funakoshi A, Kono A. Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice.Gastroenterologia Japonica 1992; 27(1): 78–82.

    PubMed  CAS  Google Scholar 

  61. Smith JP, Solomon TE, Bagheri S, Kramer S. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990.Dig Dis Sci 1990; 35(11): 1377–1384.

    Article  PubMed  CAS  Google Scholar 

  62. Smith JP, Kramer S, Bagheri S. Effects of a high-fat diet and S364-718 on growth of human pancreas cancer.Dig Dis Sci 1990; 35(6): 726–732.

    Article  PubMed  CAS  Google Scholar 

  63. Pinho E, Jamshidipour R, Moossa AR, Howell SB. Synergistic enhancement of cisplatin cytotoxicity by the cholecystokinin antagonist MK-329 in pancreatic cancer (meeting abstract).Proc Ann Meet Am Assoc Cancer Res 1992; 33: A3297.

    Google Scholar 

  64. Maani R, Townsend CM Jr, Gomez G, Thompson JC, Singh R. A potent CCK receptor antagonist (MK-329) inhibits the growth of human pancreatic cancer in nude mice.Gastroenterology 1988; 94: A274 (abstract).

    Google Scholar 

  65. Abbruzzese JL, Gholson CF, Daugherty K, Larson E, DuBrow R, Berlin R, Levin B. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer.Pancreas 1992; 7(2): 165–171.

    Article  PubMed  CAS  Google Scholar 

  66. Steffensrud S, Erichsen H, Roysland P, Halvorsen TB, Klepp R, Klepp O, Wunsch E, Petersen H. Treatment with secretin and a cholecystokinin-like peptide in patients with pancreatic cancer.Scand J Gastroenterol 1984; 19: 909–915.

    PubMed  CAS  Google Scholar 

  67. Douglas BR, Woutersen RA, Jansen JBMJ, Rovati LC, Lamers CBHW. Study into the role of cholecystokinin in bombesin-stimulated pancreatic growth in rats and hamsters.Eur J Pharmacol 1989; 161: 209–214.

    Article  PubMed  CAS  Google Scholar 

  68. Meijers M, Appel MJ, Van Garderen-Hoetmer A, Lamers CBHW, Rovati LC, Jansen JBMJ, Woutersen RA. Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumors in rats: modulation by the cholecystokinin receptor antagonist lorglumide.Carcinogenesis 1992; 13(9): 1525–1528.

    Article  PubMed  CAS  Google Scholar 

  69. Douglas BR, Woutersen RA, Jansen JBMJ, DeJong AJL, Rovati LC, Lamers CBHW. Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas.Gastroenterology 1989; 96: 462–469.

    PubMed  CAS  Google Scholar 

  70. Hajri A, Balboni G, Koenig M, Garaud JC, Damge C. Gastrin-releasing peptide:in vivo andin vitro grwoth effects on an acinar pancreatic carcinoma.Cancer Res 1992; 52: 3726–3732.

    PubMed  CAS  Google Scholar 

  71. Meijers M, Van Garderen-Hoetmer A, Lamers CB, Rovati LC, Jansen JB, Woutersen RA. Effects of bombesin on the development ofN-Nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters.Cancer Lett 1991; 59(1): 45–50.

    Article  PubMed  CAS  Google Scholar 

  72. Szepeshazi K, Schally AV, Cai RZ, Radulovic S, Milovanovic S, Szoke B. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.Cancer Res 1991; 51: 5980–5986.

    PubMed  CAS  Google Scholar 

  73. Szepeshazi K, Schally AV, Groot K, Halmos G. Effect of bombesin, gastrin-releasing peptide (GRP) (14–27) and bombesin/GRP receptor antagonist RC-3095 on grwoth of nitrosamine-induced pancreatic cancers in hamsters.Int J Cancer 1993; 54(2): 282–289.

    Article  PubMed  CAS  Google Scholar 

  74. Alexander RW, Upp JR, Poston GJ, Townsend CM Jr, Singh P, Thompson JC. Bombesin inhibits growth of human pancreatic adenocarcinoma in nude mice.Pancreas 1988; 3(3): 297–302.

    Article  PubMed  CAS  Google Scholar 

  75. Harper AA, Scratcherd T. Physiology, inThe Exocrine Pancreas, Howat HT, Sarles H, eds. Saunders, Philadelphia 1979; pp. 50–85.

    Google Scholar 

  76. Howatson AG, Carter DC. Pancreatic carcinogenesis: effect of secretin in the hamster-nitrosamine model.J Natl Cancer Inst 1987; 78: 101–105.

    PubMed  CAS  Google Scholar 

  77. Pour PM, Kazakoff K. Effect of secretin on pancreatic carcinogenesis in the hamster model.Cancer Lett 1989; 46: 57–62.

    Article  PubMed  CAS  Google Scholar 

  78. Estival A, Clemente F, Ribet A. Adenocarcinoma of the human exocrine pancreas: presence of secretin and caerulein receptors.Biochem Biophys Res Commun 1981; 102(4): 1336–1341.

    Article  PubMed  CAS  Google Scholar 

  79. Watson SA, Crosbee DM, Morris DL, Robertson JFR, Makovec F, Rovati LC, Hardcastle JD. Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumor cell growth.Br J Cancer 1992; 65: 879–883.

    PubMed  CAS  Google Scholar 

  80. Dembinsky A, Gregory H, Konturek SJ, Waterfield MD. Trophic action of epidermal growth factor on the pancreas and gastroduodenal mucosa in rats.J Physiol 1982; 325: 35–42.

    Google Scholar 

  81. Korc M, Matrisian LM, Plank SR, Magun BM. Binding of epidermal growth factor in rat pancreatic acini.Biochem Biophys Res Commun 1983; 111: 1066–1073.

    Article  PubMed  CAS  Google Scholar 

  82. Chester JF, Gaissert HA, Ross JS, Malt RA. Pancreatic cancer in the Syrian hamster induced byN-Nitrosobis(2-oxopropyl)-amine: cocarcinogenic effect of epidermal growth factor.Cancer Res 1986; 46: 2954–2957.

    PubMed  CAS  Google Scholar 

  83. Korc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer.Proc Natl Acad Sci USA 1986; 83: 5141–5144.

    Article  PubMed  CAS  Google Scholar 

  84. Massague J. Epidermal growth factor-like transforming growth factor-II. Interaction with epidermal growth factor receptors in human placenta membranes and A431 cells.J Biol Chem 1983; 258: 13,614–13,620.

    CAS  Google Scholar 

  85. Smith JJ, Derynck R, Korc M. Production of transforming growth factor a in human pancreatic cancer cells: evidence for a superagonist autocrine cycle.Proc Natl Acad Sci USA 1987; 84: 7567–7570.

    Article  PubMed  CAS  Google Scholar 

  86. Takeda Y, Escribano MJ. Effects of insulin and somatostatin on the growth and colony formation of two human pancreatic cancer cell lines.J Cancer Res Clin Oncol 1991; 117: 416–420.

    Article  PubMed  CAS  Google Scholar 

  87. Fisher WE, Boros LG, Schiemer WJ. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors.J Surg Res 1996; 63(1): 310–313.

    Article  PubMed  CAS  Google Scholar 

  88. Ohmura E, Okada M, Onoda N, Kamiya Y, Marakami H, Tsushima T, Shizume K. Insulin-like growth factor I and transforming growth factor-a as autocrine growth factor in human pancreatic cancer cell growth.Cancer Res 1990; 50: 103–107.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Baylor College of Medicine, Houston VAMC, Surgical Service (112), 77030, Houston, TX

    William E. Fisher

  2. Department of Surgery, Ohio State University, Columbus, OH

    Peter Muscarella, Laszlo G. Boros & William J. Schirmer

Authors
  1. William E. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Muscarella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laszlo G. Boros
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William J. Schirmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fisher, W.E., Muscarella, P., Boros, L.G. et al. Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma. Int J Pancreatol 24, 169–180 (1998). https://doi.org/10.1007/BF02788419

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02788419

Key Words

Search

Navigation